Skip to main content
NCD 190.29 · version 1 · Laboratory NCD

NCD 190.29: Tumor Antigen by Immunoassay - CA 15-3/CA 27.29

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.29

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
73 covered ICD-10
233 non-covered

TL;DR

NCD 190.29 sets Medicare's national policy for tumor antigen by immunoassay - ca 15-3/ca 27.29 under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy. As a laboratory NCD it carries a national ICD-10 edit list: 73 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

Immunoassay determinations of the serum levels of certain proteins or carbohydrates serve as tumor markers. When elevated, serum concentration of these markers may reflect tumor size and grade. This policy specifically addresses the following tumor antigens: CA 15-3 and CA 27.29

Indications and limitations of coverage

Indications

Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.

CA 15-3 is often medically necessary to aid in the management of patients with breast cancer. Serial testing must be used in conjunction with other clinical methods for monitoring breast cancer. For monitoring, if medically necessary, use consistently either CA 15-3 or CA 27.29, not both.

CA 27.29 is equivalent to CA 15-3 in its usage in management of patients with breast cancer.

Limitations

These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.29 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 73 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.29
CodeCode set
86300CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $20.81, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.29 edits, October 2026
CodeCLFS amountWith QWPricing
86300$20.81—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 73 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.29 (sample)
ICD-10-CMDescriptionEffective
C44.1321Sebaceous cell carcinoma of skin of right upper eyelid, including canthus2018-10-01
C44.1322Sebaceous cell carcinoma of skin of right lower eyelid, including canthus2018-10-01
C44.1391Sebaceous cell carcinoma of skin of left upper eyelid, including canthus2018-10-01
C44.1392Sebaceous cell carcinoma of skin of left lower eyelid, including canthus2018-10-01
C50.011Malignant neoplasm of nipple and areola, right female breast2015-10-01
C50.012Malignant neoplasm of nipple and areola, left female breast2015-10-01
C50.019Malignant neoplasm of nipple and areola, unspecified female breast2015-10-01
C50.021Malignant neoplasm of nipple and areola, right male breast2015-10-01
C50.022Malignant neoplasm of nipple and areola, left male breast2015-10-01
C50.029Malignant neoplasm of nipple and areola, unspecified male breast2015-10-01
C50.111Malignant neoplasm of central portion of right female breast2015-10-01
C50.112Malignant neoplasm of central portion of left female breast2015-10-01
C50.119Malignant neoplasm of central portion of unspecified female breast2015-10-01
C50.121Malignant neoplasm of central portion of right male breast2015-10-01
C50.122Malignant neoplasm of central portion of left male breast2015-10-01
C50.129Malignant neoplasm of central portion of unspecified male breast2015-10-01
C50.211Malignant neoplasm of upper-inner quadrant of right female breast2015-10-01
C50.212Malignant neoplasm of upper-inner quadrant of left female breast2015-10-01
C50.219Malignant neoplasm of upper-inner quadrant of unspecified female breast2015-10-01
C50.221Malignant neoplasm of upper-inner quadrant of right male breast2015-10-01
C50.222Malignant neoplasm of upper-inner quadrant of left male breast2015-10-01
C50.229Malignant neoplasm of upper-inner quadrant of unspecified male breast2015-10-01
C50.311Malignant neoplasm of lower-inner quadrant of right female breast2015-10-01
C50.312Malignant neoplasm of lower-inner quadrant of left female breast2015-10-01
C50.319Malignant neoplasm of lower-inner quadrant of unspecified female breast2015-10-01
C50.321Malignant neoplasm of lower-inner quadrant of right male breast2015-10-01
C50.322Malignant neoplasm of lower-inner quadrant of left male breast2015-10-01
C50.329Malignant neoplasm of lower-inner quadrant of unspecified male breast2015-10-01
C50.411Malignant neoplasm of upper-outer quadrant of right female breast2015-10-01
C50.412Malignant neoplasm of upper-outer quadrant of left female breast2015-10-01
C50.419Malignant neoplasm of upper-outer quadrant of unspecified female breast2015-10-01
C50.421Malignant neoplasm of upper-outer quadrant of right male breast2015-10-01
C50.422Malignant neoplasm of upper-outer quadrant of left male breast2015-10-01
C50.429Malignant neoplasm of upper-outer quadrant of unspecified male breast2015-10-01
C50.511Malignant neoplasm of lower-outer quadrant of right female breast2015-10-01
C50.512Malignant neoplasm of lower-outer quadrant of left female breast2015-10-01
C50.519Malignant neoplasm of lower-outer quadrant of unspecified female breast2015-10-01
C50.521Malignant neoplasm of lower-outer quadrant of right male breast2015-10-01
C50.522Malignant neoplasm of lower-outer quadrant of left male breast2015-10-01
C50.529Malignant neoplasm of lower-outer quadrant of unspecified male breast2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.29 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026. The last change was in January 2026, when CMS added 2 codes.

Codes on this NCD's list by release: October 2025: 304 · January 2026: 306 · October 2026: 306. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.29

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.29

What does NCD 190.29 cover?

Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.29 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.29?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.29?

The October 2026 laboratory NCD edit list contains 73 ICD-10-CM codes that support tumor antigen by immunoassay - ca 15-3/ca 27.29 (for example C44.1321 Sebaceous cell carcinoma of skin of right upper eyelid, including canthus; C44.1322 Sebaceous cell carcinoma of skin of right lower eyelid, including canthus; C44.1391 Sebaceous cell carcinoma of skin of left upper eyelid, including canthus) and 233 codes that deny. The list applies to 86300.

How often does the lab NCD code list for 190.29 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.